Interview with Luxa Biotechnology Leadership: Promising Results of RPESC-RPE-4W for Dry AMD

Heajin Kim 5/12/25 Heajin Kim 5/12/25

Interview with Luxa Biotechnology Leadership: Promising Results of RPESC-RPE-4W for Dry AMD

Read More

Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting

Heajin Kim 4/29/25 Heajin Kim 4/29/25

Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting

Read More

Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference

Heajin Kim 3/9/25 Heajin Kim 3/9/25

Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference

Read More

Luxa's stem cell therapy for dry AMD shows early promise

Heajin Kim 3/6/25 Heajin Kim 3/6/25

Luxa's stem cell therapy for dry AMD shows early promise

Read More

Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration

Heajin Kim 2/19/25 Heajin Kim 2/19/25

Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration

Read More